GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Price-to-Funds-From-Operations

GRFS (Grifols) Price-to-Funds-From-Operations : (As of Mar. 31, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Grifols Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Grifols Business Description

Industry
Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.